Filtered By:
Drug: Empagliflozin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 127 results found since Jan 2013.
Here Are the First 10 Drugs Biden Will Target for Price Negotiations
WASHINGTON (AP) — The popular diabetes treatment Jardiance and the blood thinner Eliquis are among the first drugs that will be targeted for price negotiations in effort to cut Medicare costs.
President Joe Biden’s administration on Tuesday released a list of 10 drugs for which the federal government will take a first-ever step: negotiating drug prices directly with the manufacturer.
[time-brightcove not-tgx=”true”]
The move is expected to cut costs for some patients but faces litigation from the drugmakers and heavy criticism from Republican lawmakers. It’s also a centerpiece of t...
Source: TIME: Health - August 29, 2023 Category: Consumer Health News Authors: TOM MURPHY, AMANDA SEITZ and CHRIS MEGERIAN / AP Tags: Uncategorized wire Source Type: news
Empagliflozin is associated with lower risk of cardiovascular events and all ‐cause mortality in routine care in East Asia: Results from the EMPRISE study
ConclusionsThe results suggest that both empagliflozin and SGLT2i compared with DPP-4i are associated with a lower risk of cardiovascular events and all-cause mortality in routine clinical care in East Asia.
Source: Journal of Diabetes Investigation - January 31, 2023 Category: Endocrinology Authors: Dae Jung Kim,
Wayne H ‐H Sheu,
Wook‐Jin Chung,
Daisuke Yabe,
Kyoung Hwa Ha,
Masaomi Nangaku,
Elise Chia‐Hui Tan,
Koichi Node,
Atsutaka Yasui,
Weiyu Lei,
Sunwoo Lee,
Laura Saarelainen,
Anouk Deruaz‐Luyet,
Moe H Kyaw,
Yutaka Seino,
EM Tags: ORIGINAL ARTICLE Source Type: research
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes Metab. 2023 Jan 3:101418. doi: 10.1016/j.diabet.2022.101418. Online ahead of print.ABSTRACTBACKGROUND: Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies.METHODS: The EMPRISE Europe and Asia study is a non-interventional cohort study using data from 2014-2019 in seven European (Denmark, Finland, Germany, Norway, Spain, Sweden, United Kingdom) and four Asian (Israel, Japan, South Korea, Taiwan) countries. Patients with type 2 d...
Source: Diabetes and Metabolism - January 7, 2023 Category: Endocrinology Authors: Avraham Karasik Stefanie Lanzinger Elise Chia-Hui Tan Daisuke Yabe Dae Jung Kim Wayne H-H Sheu Cheli Melzer-Cohen Reinhard W Holl Kyoung Hwa Ha Kamlesh Khunti Francesco Zaccardi Anuradhaa Subramanian Krishnarajah Nirantharakumar Thomas Nystr öm Leo Niska Source Type: research
Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu
J Clin Med. 2022 Nov 4;11(21):6544. doi: 10.3390/jcm11216544.ABSTRACTChronic hyperglycemia induces pathophysiologic pathways with negative effects on the metabolism of most substrates as well as lipids and lipoproteins, and thereby induces dyslipidemia. Thus, the diabetic milieu is commonly accompanied by different levels of atherogenic dyslipidemia, which is per se a major risk factor for subsequent complications such as atherosclerosis, coronary heart disease, acute myocardial infarction, ischemic stroke, and nephropathy. Therefore, readjusting lipid metabolism in the diabetic milieu is a major goal for preventing dyslip...
Source: Atherosclerosis - November 11, 2022 Category: Cardiology Authors: Habib Yaribeygi Mina Maleki Željko Reiner Tannaz Jamialahmadi Amirhossein Sahebkar Source Type: research
The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) Inhibitors
N Z Med J. 2022 Aug 19;135(1560):99-104.ABSTRACTThe sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin is currently funded in New Zealand for management of patients with type 2 diabetes who have an HbA1c >53mmol/mol and a high cardiovascular (CV) risk. Large clinical trials now provide strong evidence that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure, progressive kidney dysfunction, myocardial infarction, stroke and gout. Patients with or without diabetes who have a history of heart failure, including those with a preserved left ventricular ejection fraction and patients with ch...
Source: New Zealand Medical Journal - August 24, 2022 Category: General Medicine Authors: Chok G Chan Ralph Stewart Source Type: research
